Understanding TRT From a Clinical Standpoint
Testosterone replacement therapy (TRT) is one of the most prescribed and most misunderstood treatments in modern men’s health. As a practitioner, your ability to navigate TRT safely and effectively — from lab interpretation to dosing strategy — directly determines patient outcomes and practice reputation.
Who Is a Candidate for TRT?
The ideal TRT candidate presents with both symptomatic and biochemical hypogonadism. Symptoms include fatigue, low libido, erectile dysfunction, mood changes, decreased muscle mass, and increased body fat. Biochemically, total testosterone below 300 ng/dL (with confirmed symptoms) is the standard threshold, though many clinicians also consider free testosterone and SHBG levels in their assessment.
Baseline Lab Panel Before Initiating TRT
Before starting any patient on TRT, obtain a comprehensive baseline that includes: total testosterone, free testosterone, SHBG, LH, FSH, estradiol (E2), PSA, CBC (hematocrit baseline), comprehensive metabolic panel, and thyroid panel. This baseline is medico-legally important and guides your initial dosing strategy.
Common TRT Delivery Methods
Each delivery method has clinical tradeoffs. Intramuscular or subcutaneous injections (cypionate or enanthate) are most commonly used due to cost-effectiveness and flexibility in dosing. Topical gels offer stable levels but carry transference risk. Pellets provide steady-state delivery for 3–6 months but require insertion. Oral testosterone undecanoate (Jatenzo, Tlando) is FDA-approved but carries specific cardiovascular warnings.
Starting Doses and Titration
A conservative starting dose for testosterone cypionate is 100–150mg weekly (or split into twice-weekly injections to minimize peaks and troughs). Recheck labs at 6–8 weeks post-initiation. Titrate based on symptom response, total testosterone (target: 600–900 ng/dL), and hematocrit. Avoid chasing supraphysiologic levels.
Managing Estradiol and Hematocrit
Elevated estradiol (>40 pg/mL with symptoms) may warrant aromatase inhibitor use — but manage this carefully, as crashed estrogen causes joint pain, low libido, and mood disruption. Hematocrit above 54% is a red flag for cardiovascular risk and may require dose reduction or therapeutic phlebotomy.
Ongoing Monitoring Schedule
After stabilization, monitor labs every 6 months at minimum: testosterone levels, hematocrit, PSA, estradiol, and metabolic markers. Annual DRE or PSA trending is appropriate for men over 40.
Fertility Considerations
TRT suppresses the HPG axis, reducing sperm production. For patients with fertility goals, discuss alternatives — such as clomiphene citrate, HCG, or enclomiphene — that preserve or restore natural testosterone production without suppressing spermatogenesis.